{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040249","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.775949+00:00","generated_at":"2026-05-24T15:59:22.511611+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%","bullets":["10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.","Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).","Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.","Exclusive distribution agreement term extended to ten years from March 17, 2025.","PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040249","json":"https://secwatch.observer/filing/0000950170-25-040249.json","markdown":"https://secwatch.observer/filing/0000950170-25-040249.md","text":"https://secwatch.observer/filing/0000950170-25-040249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/0000950170-25-040249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/rcel-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:59:22.511611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}